The third batch of countries to open the bid quote results updated in real time...

Click to obtain documents: the national drug centralized procurement of the proposed results table (GY-YD2020-1) the third batch of 55 varieties of national procurement quotation and reduction (net transmission finishing version) of the third batch of national selection of enterprises list 21 06:45 (third batch of national drug collection and opening bid industry: generic drug industry concentration will continue to improve) the third batch of national drug centralized procurement in Shanghai.
a total of 189 enterprises participated in this procurement, resulting in 125 enterprises to be selected, 191 products to be selected, the average price reduction of the products to be selected 53%, the highest reduction of 95%.
industry insiders believe that, with the normalization of the volume of procurement into a final decision, the concentration of the generic pharmaceutical industry will continue to improve, the winning pharmaceutical companies are expected to further stabilize market share through collection, it is recommended to pay attention to the rich imitation drug echelons, large-scale production capacity, the integration of apipharma preparations leading enterprises.
(Caixin) 20: 20:28 Fosun Pharma: 5 drugs to be selected the third batch of national drug centralized procurement" Fosun Pharma announcement, the company's holding subsidiary participated in the national organization of centralized drug procurement and use of joint procurement The third batch of national drug centralized procurement tenders organized by the Office, the five drugs to be selected are non-clothta tablets, fumarate sulfate tablets, pivastatin calcium tablets, hydrochloric acid ethylamine butanol tablets and hydrochloric acid tablets.
the price of this proposed product has decreased to a certain extent compared with the original price.
(Caixin News Agency) 20, 19:43 "Shanghai Pharmaceuticals: Six products to bid for the third batch of national drug centralized procurement" Shanghai Pharmaceutical Announcement, the company's Xinyi balance, Chinese medicine and traditional medicine to participate in the joint procurement organization of the third batch of national drug centralized procurement bidding work.
approved generic drug metformin hydrochloride tablets (0.25g), hydrochloride bromoline capsules (30mg), ibuprofen slow release capsules (0.3g), right Piclonal tablets (3mg), hydrochloric acid fluoroxitin capsules (20mg) and katopli tablets (12.5mg, 25mg) are to be selected for this centralized procurement, and the company has conducted provincial selection according to the market potential of the provinces.
(Caixin News Agency) 20, 19:37 "Baiyunshan: two products to bid for the third batch of national drug centralized procurement" Baiyunshan announcement, the company's branch Baiyunshan Pharmaceutical Factory and its subsidiary holding subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. participated in the joint procurement office organized the third batch of national drug centralized procurement tender work.
This time a total of hydrochloric acid gold tablets, hydrochloric acid cyclic acid acrylic star tablets,acid sidna non-slice and cephalosporine capsule four products to participate in the bidding, of which hydrochloric acid gold tablets, hydrochloric acid cycloproxacin tablets two products to choose this centralized procurement,acid west of the non-slice, cephalosporine capsule this time failed to win the bid.
(Caixin) 20, 19:32 , the third batch of national drug centralized procurement of the proposed winning products, the average price reduction of 53%.
) The third batch of national drug centralized procurement of the proposed winning products reduced the average price by 53%.
(Caixin News Agency) 20th 18:38 "Connbey: two products to be the third batch of national drug centralized procurement" Conebe announcement, hydrochloric acid Tansorosin slow release capsules, non-nastamine tablets to be the third batch of national drug centralized procurement.
237 million yuan and 161 million yuan, respectively, in the first half of 2019 and 2020, accounting for 67.68 percent of the company's 2019 sales revenue. 3.50% and 5.04% of sales revenue of RMB3.195 billion in the first half of 2020, and sales revenue of non-amine tablets in 2019 and 2020 was 997.5 in the first half of 2020 10,000 yuan and 8.4919 million yuan, respectively, accounting for the company's 2019 sales revenue and the first half of 2020 sales revenue of 0.15% and 0.27% (Caixin) 20 17: 47 "Jiangsu Wu Zhong: hydrochloric acid quercetazine tablets to be the third batch of national drug centralized procurement" Jiangsu Wu Zhong issued a notice that the company's Suzhou Pharmaceutical Factory participated in the joint procurement office organized the third batch of national drug centralized procurement tender work.
Suzhou Pharmaceutical Factory has been through the State Drug Administration generic drug quality and efficacy consistent evaluation of the product hydrochloric acid quretazine tablets (20mg) to be the winning bid of this centralized procurement.
2019 sales revenue of the proposed winning product is approximately RMB28.7208 million, accounting for about 1.36% of the Company's 2019 operating income.
(Caixin) 20th 17:19 (third batch of national drug collection Hengrui Medicine 6 in 4 ammonia bromide by Shandong Yuxin exclusive winning bid) In this round of collection, Hengrui Pharmaceuticals has hydrochloric acid ammonia bromide tablets, non-busta, capedabin, lycra, celexib, hydrochloric acid Tansorosin slow release capsule 6 products to participate in the bidding.
it is worth mentioning that in the bidding of a total of 5 enterprises in the ammonia bromine rope, Shandong Yuxin with 0.075 yuan per piece of ultra-low price exclusive bid.
on August 20, 2020, the company and its controlling subsidiary, Guopharma Zhijun, participated in the third batch of centralized procurement of drugs organized by the National Organization for the Central Procurement and Use of Drugs organized by the Joint Procurement Office.
company's products kramycin tablets (0.25g) and the national medicine to Jun products cephalosporine dispersion tablets (0.1g) to choose this centralized procurement.
total sales revenue of these products in 2019 is about 158 million yuan, accounting for about 1.30% of the company's 2019 operating income.
(Caixin) 20 at 16:45 , the third batch of national drug collection and sanitary materials, Pfizer strong two original research lowest price of the bid meth cobaltamine, lynazine in this round of harvesting, although most of the original research varieties are due to overbidding and out, but there are no exceptions.
such as the bidders for methicilbalamphetamine and lynazine, Andersin and Pfizer both won at the lowest prices, forced local companies out of the market.
, the price of methylcobalamin tablets was 76.54 percent lower than the highest declared price, and Pfizer's strong lynazine was 90 percent lower.
(KoTron Board Daily) 20, 14:40 , "the third batch of drugs collected diabetes drug metformin price reduction of more than 90%" This morning, the third national drug centralized procurement in Shanghai, involving 56 varieties, 82 product regulations.
, diabetes drug metformin oral normal release dosage form (0.25g, 0.5g) because of the number of enterprises through consistent evaluation as high as 29, metformin slow release control release dosage form (0.5g) has 17 enterprises, competition is very fierce.
according to the lowest figures, metformin 0.5g and 0.25g two rules, the maximum price reduction of more than 90%.
(Caixin News Agency) 20th 14:39 ,East China Medicine 2 varieties of Anazole tablets, dopamine tablets are successfully winning the bid) the third batch of national drug centralized procurement declaration information public conference is being held in Shanghai.
, it is understood that two varieties of East China Medicine Anazole tablets (1mg), dopamine tablets (10mg) were successfully successfully winning the bid.
(Caixin News Agency) 20th 13:30 , the third batch of national medicine collection Baiyunshan acid West Dena non-piece bid Qilu with the floor price exclusive bid ) in this round of collection Among them, the bidding companies of Sidina non-acid have four enterprises, Pfizer, Guangzhou Baiyunshan, Qilu and Yabang Epson, and finally Qilu won the bid with more than 3 pieces, and the rest of the enterprises were out.
it is worth mentioning that Chirusidna was only approved for listing on August 17th, as if it had passed a consistent evaluation.
non-tablet dysfunction is erectile dysfunction and is a selective inhibitor of type 5 phosphate degesterase (PDE5).
2018, sales of non-tablets in China's public hospitals and urban retail pharmacies will be RMB114 million and RMB2,207 million, respectively, according to
Meter Intranet.
(Kotron Board Daily) 20th 13:03 (third batch of national drug collection titofa teb winning enterprises have sunny, Colum and other four) in this round of collection, Tofatib The bidding enterprises are Pfizer, Zhengda Tianqing, Qilu, Hunan Colum, Yangzijiang, Synsheng Pharmaceuticals 6 enterprises, the final winning enterprises are Zhengda Tianqing, Hunan Colum, Qilu, Synth Pharmaceuticals 4.
acid tofatab is the world's first small molecule for the treatment of rheumatoid arthritis targeted JAK kinase inhibitors, the original manufacturer of Pfizer, the product since its launch, global sales continue to climb, in 2017 exceeded the $1 billion mark, reached $1.345 billion, in 2018 continued to grow to $1.774 billion.
(KoCheng Board Daily) 20th 12:44 ,the third batch of national drug collection Huahai Pharmaceutical industry three varieties of the full winning bid in this round of harvesting, Huahai Pharmaceutical cocoon salt tan tablets, O nitrogen flat mouth collapse tablets and hydrochloric acid sherquoline tablets three collection varieties all winning the bid.
(Kotsun Board Daily) 20th 12:34 (third batch of national drug collection injection with Aza cytosine winning enterprise for Zhengda Tianqing, Sichuan Huiyu) in this round of collection, injection with Aza cytosine bidding enterprises have a new foundation, Zhengda Tianqing and Sichuan Huiyu 3 enterprises, the quotations are 736.5, 346 and 260, according to the rules of the three two, the final Sichuan Huiyu and Zhengda Tianqing won the bid, compared with the highest effective declared price, the two enterprises quoted 74% and 65%, respectively.
(Kocheng Board Daily) 20th 12:21 (third batch of national drug collection China Resources Sekofna amine price dropped 92.5%) In this round of mining, China Resources Shuanghe wholly-owned subsidiary Hua Runseko in the bidding for non-amine (5mg) reported an ultra-low price of 4.4 yuan (10 pieces / box), the conversion price of a single piece is only 0.44 yuan, the highest effective declared price down 92.5%.
the opening is not yet over, it is certain that the price is low enough.
5mg of amine to treat prostat growth.
(Kotron Board Daily) 20th 12:00 ,the third batch of national drug collection of foreign enterprises a large number of varieties out of this round, many foreign enterprises are too high a variety of harvesting because of the high bid (above the price limit) and early exit, including AstraZenecon's Anaqule, Lilly's O nitrogen flat-mouthed chip, Mercado's tricloretaine, Xi'an Jansen's Dopanli ketone, Roche's Capatabin, Novarma's Raccoon, GSK's Ramifding, Pfizer's Shequlin, Xi'an Jansen's Pulu Kabili, and so on.
(Kotron Board Daily) 20th 11:24 (third batch of national belt procurement in Zhengda Tianqing winning the bid Aza cytosine injection) in the third batch of national drug belt procurement morning quotation link, injection with Aza cell Glycoside original research new base / Baiji Shenzhou quotation for 736.5 yuan / box, generic drug Zhengda Tianqing quote 346 yuan / box, another generic drug Sichuan Huiyu price has not yet come out, Zhengda Tianqing basically determined the winning bid.
(Caixin News Agency) 20th 11:17 (third batch of national drug collection Red Day Pharmaceuticals Moxixa star sodium chloride injection bid) "Kotsun Board Daily" reporter in the third batch of national drug centralized procurement site learned that in the collection of sodium chloride injection, Bayer out, Red Day Pharmaceuticals and Hainan Aicco winning bid.
(Caixin) 20th 10:30 (third batch of volume procurement quotation Ramifding original research GlaxoSmithKline / Fosun Pharma did not reduce prices) in the third batch of national drug belt procurement morning quotation link, hepatitis B drug Ramif tablets Original research GlaxoSmithKline quoted 904.2 yuan / box, basically no price reduction, and other generic drug price difference is huge, such as Shijiazhuang Dikang Longze quoted 11.94 yuan / box, Fosun Pharma has GlaxoSmithKline this variety of China market interests.
(Caixin) 20th 09:31 (third batch of national drug collection opened today close to 200 enterprises to participate in the tender) the third batch of national drug collection today (20th) opened the tender, it is understood that this round of collection of about 200 enterprises to participate in the bidding, including more than 50 listed companies.
Among them, Yangzijiang Pharmaceuticals, Shi Pharmaceutical Group, Qilu Pharmaceuticals, Shanghai Pharmaceuticals, Hengrui Pharmaceuticals, Colum Pharmaceuticals, etc. are involved in this collection of more varieties of enterprises, but also domestic generic pharmaceutical head enterprises.
addition, in order to ensure the seriousness and normal order of the collection site, the joint acquisition or will also be radio signal shielding, all mobile phones and other radio communication equipment during the opening of the tender can not be used normally.
(Kotsun Board Daily)